Literature DB >> 16412989

Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.

Joseph Levine1, Ziva Stahl, Ben-Ami Sela, Vladimir Ruderman, Oleg Shumaico, Ivgeny Babushkin, Yamima Osher, Yuly Bersudsky, R H Belmaker.   

Abstract

BACKGROUND: An elevated homocysteine level is reported to be a risk factor for several diseases, including Alzheimer's and cerebrovascular disease. Recently, several studies have reported that homocysteine levels are elevated in many schizophrenic patients. Homocysteine levels can be lowered by oral folic acid, B-12, and pyridoxine.
METHODS: Forty-two schizophrenic patients with plasma homocysteine levels >15 micromol/L were treated with these vitamins for 3 months and placebo for 3 months in a study with a randomized, double-blind, placebo-controlled, crossover design.
RESULTS: Homocysteine levels declined with vitamin therapy compared with placebo in all patients except for one noncompliant subject. Clinical symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale declined significantly with active treatment compared with placebo. Neuropsychological test results overall, and Wisconsin Card Sort (Categories Completed) test results in particular, were significantly better after vitamin treatment than after placebo.
CONCLUSIONS: A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412989     DOI: 10.1016/j.biopsych.2005.10.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  33 in total

1.  Homocysteine and cognition in first-episode psychosis patients.

Authors:  Rosa Ayesa-Arriola; Rocío Pérez-Iglesias; José Manuel Rodríguez-Sánchez; Ignacio Mata; Elsa Gómez-Ruiz; Maite García-Unzueta; Obdulia Martínez-García; Rafael Tabares-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-02       Impact factor: 5.270

Review 2.  Vitamin supplementation in the treatment of schizophrenia.

Authors:  Hannah E Brown; Joshua L Roffman
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

3.  Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis.

Authors:  Yukiko Tomioka; Shusuke Numata; Makoto Kinoshita; Hidehiro Umehara; Shin-Ya Watanabe; Masahito Nakataki; Yoshimi Iwayama; Tomoko Toyota; Masashi Ikeda; Hidenaga Yamamori; Shinji Shimodera; Atsushi Tajima; Ryota Hashimoto; Nakao Iwata; Takeo Yoshikawa; Tetsuro Ohmori
Journal:  J Psychiatry Neurosci       Date:  2018-05       Impact factor: 6.186

4.  Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.

Authors:  Kenji Sakuma; Shinji Matsunaga; Ikuo Nomura; Makoto Okuya; Taro Kishi; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

Review 5.  Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed.

Authors:  Tahireh A Shams; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

6.  Age Matters: an Atypical Association Between Polymorphism of MTHFR and Clinical Phenotypes in Children with Schizophrenia.

Authors:  Lin Wan; Yuhong Li; Yuming Zhou; Rena Li; Yi Zheng
Journal:  J Mol Neurosci       Date:  2019-07-13       Impact factor: 3.444

Review 7.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

8.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

9.  Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia.

Authors:  Susan J van Rensburg; Cornelius M Smuts; Dinie Hon; Martin Kidd; Sulene van der Merwe; Christo Myburgh; Piet Oosthuizen; Robin Emsley
Journal:  Metab Brain Dis       Date:  2009-10-14       Impact factor: 3.584

10.  Clinical features of schizophrenia with enhanced carbonyl stress.

Authors:  Mitsuhiro Miyashita; Makoto Arai; Akiko Kobori; Tomoe Ichikawa; Kazuya Toriumi; Kazuhiro Niizato; Kenichi Oshima; Yuji Okazaki; Takeo Yoshikawa; Naoji Amano; Toshio Miyata; Masanari Itokawa
Journal:  Schizophr Bull       Date:  2013-09-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.